Can antidepressant use be associated with emotional blunting in a subset of patients with depression? A scoping review of available literature

© 2023 John Wiley & Sons Ltd..

INTRODUCTION: Despite frequent recognition of emotional blunting in the published literature, either as a primary symptom of depression or as an adverse effect of antidepressants, there is no systematic synthesis on this topic to our knowledge. We undertook this scoping review to assess the prevalence, clinical features, implicated causes and management of emotional blunting, outlining the phenomenological and clinical gaps in research.

METHOD: A systematic search was done until March 15, 2022, to include all original studies (i.e., interventional trials, cohort & cross-sectional studies, case reports, and case series). All reviewed data were delineated to answer pertinent clinical, phenomenological, and management questions related to the phenomenon of emotional blunting.

RESULTS: A total of 25 original studies were included in our scoping review. Emotional blunting was described as a persistent diminution in both positive and negative feelings in depressed patients, who could subjectively differentiate it from their acute symptoms. However, the literature lacked the distinction between emotional blunting as a primary symptom of depression or an adverse effect of antidepressants. Common clinical strategies to manage antidepressant-induced emotional blunting included dose reduction or switching to a different antidepressant.

CONCLUSION: Emotional blunting was a significant patient-reported concern with antidepressants. Future research should clarify phenomenological and neurobiological constructs underlying emotional blunting to improve diagnostic and management skills.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:38

Enthalten in:

Human psychopharmacology - 38(2023), 4 vom: 15. Juli, Seite e2871

Sprache:

Englisch

Beteiligte Personen:

Jawad, Muhammad Youshay [VerfasserIn]
Fatima, Maurish [VerfasserIn]
Hassan, Umer [VerfasserIn]
Zaheer, Zaofashan [VerfasserIn]
Ayyan, Muhammad [VerfasserIn]
Ehsan, Muhammad [VerfasserIn]
Khan, Muhmmad Huzaifa Ahmed [VerfasserIn]
Qadeer, Ahsan [VerfasserIn]
Gull, Abdul Rehman [VerfasserIn]
Asif, Muhammad Talha [VerfasserIn]
Shad, Mujeeb U [VerfasserIn]

Links:

Volltext

Themen:

Anhedonia
Antidepressant adverse effects
Antidepressive Agents
Emotional adverse effects
Emotional blunting
Journal Article
Major depressive disorder
Review

Anmerkungen:

Date Completed 10.07.2023

Date Revised 16.11.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1002/hup.2871

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM35686832X